Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neutropenia 3Neoplasms 2Febrile Neutropenia 2Urinary Tract Infections 1Testicular Neoplasms 1Staphylococcal Infections 1Spasm 1Sleep Initiation and Maintenance Disorders 1Sezary Syndrome 1Sepsis 1Seizures 1Schizophrenia, Treatment-Resistant 1Schizophrenia 1Retinitis 1Renal Insufficiency, Chronic 1Pulmonary Arterial Hypertension 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pneumonia 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Pain 1Other Infectious Diseases 1Neoplasms, Plasma Cell 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Multiple Myeloma 1Migraine Disorders 1Menorrhagia 1Meningitis, Bacterial 1

Interventions

ceftolozane 1Tazobactam 1Piperacillin, Tazobactam Drug Combination 1Meropenem 1Cefepime 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Other Infectious Diseases × Cefepime × Clear all
NCT03485950 2022-03-15

Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam

M.D. Anderson Cancer Center

Phase 2 Completed
100 enrolled 33 charts

Other Infectious Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡